

NG MILLS LIMITED CIN: L16100TG1983PLC003961

Madhapur, Mahabubnagar District 509 202, Telangana.
P. Road, Secunderabad 500 003, Telangana.

FOR THE QUARTER ENDED 31ST DECEMBER 2016 (Rs. in Lakhs)

	Quarter Ended 31.12.2016 Unaudited	Year Ended 31.03.2016 Audited	Quarter Ended 31.12.2015 Unaudited
Extra- Ordinary Items)	1761.00 (3508.00)	36763.00 (2108.00)	10170.00 (694.00)
balance sheet of	3508.00 1965.61	(2108.00) 1965.61	(694.00) 1965.61
(Of Rs. 10/- each)	-	-	1419.44
(Of Rs. 10/- each)	(17.84) (17.84)	(10.72) (10.72)	(3.53) (3.53)
	(17.84) (17.84)	(10.72) (10.72)	(3.53) (3.53)

for SURYAJYOTI SPINNING MILLS LIMITED

sd/-
A.K.AGARWAL
EXECUTIVE DIRECTOR
Place : Secunderabad
Date : 14.02.2017



VAMSHI RUBBER LIMITED

ISO 9001:2008
COMPANY

CIN: L25100TG1993PLC016634
Regd. Office: 'VAMSHI HOUSE', Plot No. 41,
Jayabheri Enclave, Gachibowli, Hyderabad-500032, Telangana
E-Mail: info@vamshirubber.org, Website: www.vamshirubber.org

EXTRACT FROM THE STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DEC, 2016 (RS. IN LAKHS)

Sr. No.	PARTICULARS	QUARTER ENDED 31-12-2016 Un-Audited	YEAR ENDED 31-03-2016 Audited	QUARTER ENDED 31-12-2015 Un-Audited
1.	Total Income from operations	1,521.75	6,620.68	1,713.63
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(61.99)	201.79	71.52
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(61.99)	201.79	71.52
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(43.10)	130.95	43.60
5.	Total Comprehensive Income for the period (comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (After tax)	(43.10)	130.95	43.60
6.	Equity Share Capital	420.68	420.68	420.68
7.	Reserves excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	1086.47	1086.47	1,006.15
8.	Earning Per Share (after extraordinary items) (of Rs.10/- each)			
	(a) Basic (in Rs.)	(1.02)	3.11	1.04
	(b) Diluted (in Rs.)	(1.02)	3.11	1.04

NOTE:
1)The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges websites, www.bseindia.com and website of the Company www.vamshirubber.org

By the Order of the Board
for Vamshi Rubber Limited
sd/-
M. Ramesh Reddy
Chairman & CFO
DIN: 00025101

Place: Hyderabad
Date: 14-02-2017

R PRODUCTS LIMITED

HOUSE, Madhapur, Hyderabad-500 081,
mail : investors.nccbpl.com, Website : www.nccbpl.com
STG1992PLC014678)

the quarter and nine months ended 31st December, 2016 (Rs.in lakhs)

	Quarter ended 31.12.2016	Nine Months ended 31.12.2016	Quarter ended 31.12.2015
	11.09	683.15	6.85
	11.09	683.15	6.85
	11.07	683.15	6.85
	775.00	775.00	775.00
	0.14	8.81	0.09

By order of the Board
for NCC Bluewater Products Limited
U Jayachandra
Director
Place : Hyderabad
Date : 14.02.2017

ITED

CIN: L65993TG1994PLC017737
HOUSE, Madhapur, Hyderabad-500 081, Tel : 040-23268888
estors.nccfi@yahoo.com, Website : www.nccfinanceltd.com

ter and nine months ended 31st December, 2016 (₹ in Lakhs)

	Quarter Ended 31.12.2016	Nine Months Ended 31.12.2016	Quarter Ended 31.12.2015
ceptional and	6.50	2.64	(0.70)
er Exceptional	6.50	2.64	(0.70)
er Exceptional	6.50	2.64	(0.70)
₹ (595.67)	602.40	602.40	602.40
(31.03.2016)	0.10	0.04	(0.01)

By order of the Board
for NCC Finance Limited

COMBAT DRUGS LIMITED

9-109/9, PLOT NO.112, ROAD NO:14, GAYATRI NAGAR, BODUPPAL, R.R.DISTRICT-500 039, TELANGANA
(CIN NO. CL23230TG1986PLC006781), URL: www.combatdrugs.in, Mail: info@combatdrugs.in

EXTRACT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER, 2016 (Rs in Lakhs)

Sl. No.	Particulars	Quarter Ended 31.12.16	Year to Date 31.12.16	Quarter Ended 31.12.15
1.	Total Income from Operations (Net)	15.31	28.23	9.91
2.	Net (Loss) for the period before Tax (before Extraordinary items)	(5.28)	(19.24)	(1.73)
3.	Net (Loss) for the period before Tax (After Extraordinary items)	(5.28)	(19.24)	(1.73)
4.	Net (Loss) for the period after Tax (After Extraordinary items)	(5.28)	(19.24)	(1.73)
5.	Total Comprehensive Income for the period	(5.28)	(19.24)	(1.73)
6.	Equity Share Capital	800.00	800.00	800.00
7.	Reserves			
8.	Basic & Diluted Earning per Share (of Rs.10/- each)			
	i. Basic	(0.07)	(0.24)	(0.00)
	ii. Diluted	(0.07)	(0.24)	(0.00)

Notes:
1.The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the stock exchanges under Regulation 33of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Results along with limited Review Report are available on the Stock Exchange Website www.bseindia.com and on Companys website www.combatdrugs.in.
2.Previous year/s / period's figures have been regrouped / rearranged / recasted wherever necessary.
3.The above Financial Results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 14th February 2017.

By order of the Board
For Combat Drugs Limited
sd/-
S M Lal
Director

Place: Hyderabad
Date:14-02-2017



Combat Drugs Limited

Regd. Off: 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Bouduppall, R.R.District -500039, TS
Ph: +91-40-66200100 / 65523363 Url: www.combatdrugs.in Email: info@combatdrugs.in
CIN No.: L24230TG1986PLC006781 TIN: 36690236431 D.L.No.: TG/15/04/2016-14766

14/02/2017

To,
The General Manager
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001

Sir,

Sub: Outcome of Board Meeting – Approval of Quarterly Results
(Quarter ended 31st December, 2016)

Pursuant to Regulation 29 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that at the meeting of the Board of Directors of the company held today ie; 14th February, 2017, the Statement of Un-Audited Financial Results for the quarter ended 31st December, 2016 was approved and taken on record along with the Limited Review Report for the period issued by the Statutory Auditors of the company.

Please find enclosed the following in respect of the above said:

1. Statement of Un-Audited Financial Results for the Quarter ended 31st Dec, 2016.
2. Limited Review Report of the Auditors on Quarterly Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking You

Yours Sincerely,

For **COMBAT DRUGS LIMITED**

Kiran Kumar K

COMPLIANCE OFFICER



COMBAT DRUGS LIMITED (CIN NO. CL23230TG1986PLC006781)	Regd.off.:9-109/9, Plot No.112, Rd No.14, Gayatri Nagar, Bouduppall (V), R.R.Dist Hyderabad ,Telangana ,500039	Ph: 040-65523363 / 66200100 URL: www.combatdrugs.in Mail: info@combatdrugs.in
---	--	---

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2016

Amount - Rs. In lakhs

Particulars	Quarter Ended			9 Months Ended		Year Ended
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	31.03.2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
PART - I						
1. Income from Operations						
1 (a) Net Sales/Income from Operations (net of excise duty)	15.31	9.85	9.91	28.23	16.84	22.30
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Total income from operations (net)	15.31	9.85	9.91	28.23	16.84	22.30
2. Expenses						
a. Cost of materials consumed	12.00	5.13	2.83	19.70	8.10	11.30
b. Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
c. Changes in inventories of Finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
d. Employees benefits expense	7.02	5.09	1.53	16.19	4.59	12.38
e. Depreciation	0.00	0.00	2.85	0.00	8.56	8.56
f. Expired stocks	0.00	0.00	0.00	0.00	0.00	39.92
g. Other expenses	1.57	5.45	4.68	11.58	17.93	78.46
Total	20.59	15.67	11.89	47.47	39.18	150.62
3 Profit / (Loss) from Operations before Other Income, finance costs and Exceptional Items	(5.28)	(5.82)	(1.98)	(19.24)	(22.34)	(128.32)
4 Other Income	0.00	0.00	0.25	0.00	0.40	0.55
5 Profit / (Loss) from ordinary activities before finance costs and Exceptional Items (3+4)	(5.28)	(5.82)	(1.73)	(19.24)	(21.94)	(127.77)
6 Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit / (Loss) from ordinary activities after finance costs but before Exceptional Items (5-6)	(5.28)	(5.82)	(1.73)	(19.24)	(21.94)	(127.77)
8 Exceptional items	0.00	0.00	0.00	0.00	28.81	0.00
9 Profit / (Loss) from Ordinary Activities before tax (7+8)	(5.28)	(5.82)	(1.73)	(19.24)	(50.75)	(127.77)
10 Tax expense	0.00	0.00	0.00	0.00	0.00	0.00
11 Net Profit / (Loss) from Ordinary Activities after tax (9+10)	(5.28)	(5.82)	(1.73)	(19.24)	(50.75)	(127.77)
12 Extraordinary Item (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13 Net Profit / (Loss) for the period (11-12)	(5.28)	(5.82)	(1.73)	(19.24)	(50.75)	(127.77)
14 Share of Profit / (Loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority interest	0.00	0.00	0.00	0.00	0.00	0.00
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	(5.28)	(5.82)	(1.73)	(19.24)	(50.75)	(127.77)
17 Paid-up equity share capital (Face value of the Share shall be indicated) - Face value Rs. 10/-	800.00	800.00	800.00	800.00	800.00	800.00
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	-	0.00	0.00
19 i) Earnings per Share (before extraordinary items) of Rs. /- each (not annualised):						
(a) Basic	(0.07)	(0.07)	0.00	(0.24)	(0.06)	(1.60)
(b) Diluted	(0.07)	(0.07)	0.00	(0.24)	(0.06)	(1.60)
ii) Earning per share (after extraordinary items)						
(a) Basic	(0.07)	(0.07)	0.00	(0.24)	(0.06)	(1.60)
(b) Diluted	(0.07)	(0.07)	0.00	(0.24)	(0.06)	(1.60)

Notes

- The above Financial Results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 14th Feb, 2017.
- The Company is operating in only one segment i.e, Pharmaceuticals and hence segment – wise reporting is not made.
- Previous year/s / period's figures have been regrouped / rearranged / recasted wherever necessary.

For and on behalf of the Board of Directors

Place: Hyderabad

Date : 14.02.2017



DIRECTOR



M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


To
The Board of Directors of
Combat Drugs Limited


We have reviewed the accompanying Statement of Unaudited Financial Results of Combat Drugs Limited for the Quarter and nine months ended 31st December, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,
Chartered Accountants
(FRN: 000125S)


A.V. Sadasiva
Partner
Membership No.018404



Place: Secunderabad
Date: 14th February, 2017